Last updated on January 2019

Trial Assessing Efficacy Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders


Brief description of study

A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.

Detailed Study Description

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo,when added to standard of care, on percent change from baseline in lowdensity lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH

Clinical Study Identifier: NCT02392559

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Pretoria, South Africa
1.89miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.